<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-12-05">December 5, 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Oliver</forename><surname>Schmetzer</surname></persName>
							<email>oliver.schmetzer@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<address>
									<settlement>Charit e-Universit€ atsmedizin Berlin</settlement>
								</address>
							</affiliation>
							<affiliation key="aff0">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<address>
									<settlement>Charit e-Universit€ atsmedizin Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Elisa</forename><surname>Lakin</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<address>
									<settlement>Charit e-Universit€ atsmedizin Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fatih</forename><forename type="middle">A</forename><surname>Topal</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<address>
									<settlement>Charit e-Universit€ atsmedizin Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Patricia</forename><surname>Preusse</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<address>
									<settlement>Charit e-Universit€ atsmedizin Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Denise</forename><surname>Freier</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<address>
									<settlement>Charit e-Universit€ atsmedizin Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD, DSc</roleName><forename type="first">Martin</forename><forename type="middle">K</forename><surname>Church</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<address>
									<settlement>Charit e-Universit€ atsmedizin Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Marcus</forename><surname>Maurer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<address>
									<settlement>Charit e-Universit€ atsmedizin Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-12-05">December 5, 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">778A30204D8D559912FC03AF7ED1CA7E</idno>
					<idno type="DOI">10.1016/j.jaci.2017.10.035</idno>
					<note type="submission">Received for publication December 21, 2016; revised September 22, 2017; accepted for publication October 16, 2017.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:27+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>IL-24, IgE, autoantibody, autoallergen, autoallergy, type I hypersensitivity, chronic spontaneous urticaria, wheal and flare, protein microarray, urticaria activity score FAES Pharma, Menarini, MSD, Novartis, UCB Pharma, Sanofi-Aventis, and Uriach</term>
					<term>and has received payment for manuscript preparation from FAES Pharma. M. Maurer has board memberships with Novartis, Genentech, Uriach, Menarini, FAES, and Moxie</term>
					<term>has consultant arrangements with Novartis, Genentech, Uriach, Menarini, FAES, and Moxie</term>
					<term>has provided expert testimony for Novartis, Genentech, Uriach, Menarini, FAES, and Moxie</term>
					<term>has received grants from Novartis, Genentech, Uriach, Menarini, FAES, and Moxie</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: The efficacy of omalizumab (anti-IgE) and increased IgE levels in patients with chronic spontaneous urticaria (CSU) suggest autoallergic mechanisms.</s><s>Objective: We sought to identify autoallergic targets of IgE in patients with CSU.</s><s>Methods: Serum samples of patients with CSU together with those of patients with idiopathic anaphylaxis and healthy control subjects (7 of each) were screened for IgE autoantibodies by using an array of more than 9000 proteins.</s><s>Sera of 1062 patients with CSU and 482 healthy control subjects were used in an IgE-anti-IL-24-specific ELISA to investigate the association of IgE-anti-IL-24 and CSU.</s><s>Results: By using array analyses, more than 200 IgE autoantigens were found in patients with CSU that were not found in control subjects.</s><s>Of the 31 IgE autoantigens detected in more than 70% of patients, 8 were soluble or membrane bound and expressed in the skin.</s><s>Of these, only IgE autoantibodies to IL-24 were found in all patients with CSU.</s><s>In vitro studies showed IL-24 to release histamine from human mast cells sensitized with purified IgE of patients with CSU but not control subjects.</s><s>By using ELISA, mean 6 SD levels of IgE-anti-IL-24 were 0.52 6 0.24 IU/mL in patients with CSU and 0.27 6 0.08 IU/mL in control subjects, with 80% of patients with CSU but only 20% of control subjects having levels greater than 0.33 IU/ mL (P &lt; .0001).</s><s>IgE-anti-IL-24 showed acceptable predictive properties for CSU, with a likelihood ratio of 3.9.</s><s>Clinically, IgE-anti-IL-24 levels showed an association with disease activity, as assessed by the urticaria activity score and with reduced basophil counts.</s><s>Conclusion: Our findings show that patients with CSU frequently exhibit IgE autoantibodies against many autoantigens and that IL-24 is a common, specific, and functional autoantigen of IgE antibodies in patients with CSU.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>It has been 75 years since it was first suggested that the production of wheals in patients with urticaria might have an underlying allergic mechanism. <ref type="bibr" target="#b0">1</ref></s><s>Certainly, the effectiveness of H 1 -antihistamines in patients with urticaria <ref type="bibr" target="#b1">2</ref> would support this hypothesis, even though no obvious extrinsic allergens have been identified.</s><s>This prompted Rorsman <ref type="bibr" target="#b2">3</ref> to suggest urticaria to be an autoallergy (ie, type I hypersensitivity to selfallergens).</s><s>The involvement of IgE in patients with urticaria was suggested from 2 sources.</s><s>5]<ref type="bibr" target="#b5">[6]</ref> Second is the effectiveness of omalizumab (anti-IgE) in relieving the symptoms of CSU. <ref type="bibr" target="#b6">7</ref> In patients with other autoimmune conditions, such as systemic lupus erythematosus, the disease is complex and characterized by production of autoantibodies to a broad range of self-antigens. <ref type="bibr" target="#b7">8</ref></s><s>or example, in patients with systemic lupus erythematosus, IgE antibodies specific for double-stranded DNA have been suggested to stimulate plasmacytoid dendritic cells, an immune cell linked to viral defense, to secrete substantial amounts of IFN-a. <ref type="bibr" target="#b8">9</ref></s><s>e postulate that CSU is an autoimmune disease in which IgE recognizes several autoantigens that are probably primarily dermal in origin.</s><s>Low-level diffusion of these into the bloodstream would be consistent with the basopenia seen in patients with CSU. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b9">10</ref></s><s>Furthermore, periods of increased local generation of such allergens would explain the localized exacerbations of CSU.</s></p><p><s>To test this hypothesis, large-scale screening of autoreactive IgE in the serum of patients with CSU was used to explore potential targets of IgE autoantibodies (IgE-AAbs) in patients with this disease.</s><s>IgE present in sera from patients with idiopathic anaphylaxis (IdA) and healthy subjects was used as a control.</s><s>The association of the primary IgE autoantibody was further investigated both in vitro and clinically.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Serum from patients with CSU and control subjects</head><p><s>We analyzed 1062 patients with CSU (73% female), 7 patients with IdA (57% female), and 482 healthy control subjects (61% female).</s><s>There was no significant difference between the ages of patients with CSU (mean 6 SD, 44.0 6 14.7 years), patients with IdA (44.4 6 13 years), and healthy control subjects (46.9 6 16.7 years).</s></p><p><s>All patients were treated at our specialized outpatient clinic for dermatologic allergology.</s><s>They were given a diagnosis of CSU or IdA in line with the current World Allergy Organization ''Guidelines for the assessment and management of anaphylaxis'' and the European Academy of Allergy and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum/World Allergy Organization urticaria guidelines, respectively.</s><s>None of the patients with CSU had concomitant IdA, and none of the patients with IdA had CSU, thus excluding overlap in the patients analyzed by using microarray analyses.</s><s>We did not systematically assess autoimmune comorbidities in the study subjects.</s></p><p><s>In our patients with CSU, the mean duration of disease was 5.0 years, and the mean 7-day urticaria activity score (UAS7) 2 was 16.7.</s><s>Fifty percent of patients with CSU had angioedema, and 26% had positive autologous serum skin test reactions, which were defined as being greater than 2 mm compared with those elicited by the negative control.</s></p><p><s>Blood was taken from all study subjects, and serum was separated after clot formation without the use of a clotting enhancer.</s><s>After separation, serum was frozen immediately and stored at 2808C until used for microarray, ELISA, or IgE purification for functional studies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics statement</head><p><s>Blood samples taken from patients and all material investigated in this study were used after written informed consent, as approved by the ethics committee of the Charit e-Universit€ atsmedizin Berlin (EA1-329-14 and EA1-292-14), according to the Declaration of Helsinki (59th WMA General Assembly, Seoul, Korea; October 2008).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Auto-IgEome analyses using a microarray</head><p><s>One milliliter of serum from 7 patients with CSU, 7 patients with IdA, and 7 healthy control subjects was incubated on a ProtoArray Human Protein Microarray (version 5.1; Thermo Fisher, Waltham, Mass) at room temperature for 1 hour.</s><s>This microarray contains 9374 unique, full-length human proteins.</s><s>The slide was then washed 3 times with PBS with 0.05% Tween-20 (TPBS; Sigma, Munich, Germany) and incubated with 1 mL of staining solution for 30 minutes in the dark (1 mg/mL each of mouse anti-human IgGphycoerythrin [clone G18-145] and mouse anti-human IgE-allophycocyanin [clone MHE-18; both from BioLegend, San Diego, Calif]) in 2% human albumin (clinical grade [Baxter, Unterschleißheim, Germany] in TPBS).</s><s>Thereafter, the slide was washed extensively with TPBS, followed by 3 washes with water and measurement at a resolution of 2 mm in a PowerScanner (Tecan, M€ annedorf, Switzerland).</s><s>Specificity of mAbs was tested on nonserum-treated chips to remove off-target bindings.</s><s>The signal was calculated as mean or z scores, and signals corresponding to immunoglobulin-binding proteins (TRIM domain-containing or FcR proteins) were removed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quantification of IgE-anti-IL-24 function</head><p><s>The functionality of IgE-anti-IL-24 was tested by using histamine release from peripheral CD34 1 stem cell-derived mast cells (PSCMCs), which were prepared as previously described. <ref type="bibr" target="#b10">11</ref></s><s>Briefly, CD34 1 cells (STEMCELL Technologies, Cologne, Germany) were cultured with rIL-3 and stem cell factor (both from Miltenyi Biotec, Bergisch Gladbach, Germany) for 2 weeks in SFEM medium containing human LDL (STEMCELL Technologies).</s></p><p><s>Beads for IgE purification were prepared with 1 mg of anti-IgE mab (clone MB10-5C4; Miltenyi Biotec) conjugated to NHS-mag Sepharose (GE, Frankfurt am Main, Germany) and blocked with 100 mmol/L ethanolamine in 1 mol/L Tris (pH 8.0; Sigma).</s><s>Total IgE was purified from 1 L of pooled serum from patients with CSU or healthy subjects by using these beads after 24 hours of incubation at 48C.</s><s>Beads were washed with TPBS, and IgE was eluted with 0.1 mol/L citrate buffer (Sigma) at pH 2 and stabilized with 1 mol/L Tris (pH 8.0).</s><s>PSCMCs were diluted to 2 3 10 5 /mL in 10 mL of SFEM medium (STEMCELL Technologies) containing 250 mL (5 10 mg) of total IgE preparation and incubated overnight at 378C.</s></p><p><s>Ninety-six-well plates were coated overnight at 378C with 0.5 mg of IL-24 (Miltenyi Biotec) per well in carbonate buffer (pH 9).</s><s>Plates were blocked for 2 hours at room temperature with 2% human serum albumin in PBS.</s><s>IgEloaded PSCMCs were washed with RPMI (Thermo Fisher) and added to the plates to a final concentration of 80,000 cells per well in 0.2 mL of SFEM medium.</s><s>In addition to the coated wells, further wells were submitted to anti-IgE (1 mg/well), 1% Triton-X, or nothing for 30 minutes at 378C.</s><s>Thereafter, plates were centrifuged at 400g for 8 minutes to deplete cells.</s><s>Supernatants were stored in 2808C until histamine measurement in a HISTAREADER (Reflab, Copenhagen, Denmark).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IgE-anti-IL-24 measurements by means of ELISA</head><p><s>Sixteen micrograms of anti-IgE (MHE-18; BioLegend) were dispensed in 10 mL of Coating Buffer (0.1 mol/L carbonate [pH 9]; Sigma), and 25 mL of this solution was used per well in a black NUNC Maxi-Sorb 384-well plate (Thermo Fisher) to coat at 48C overnight.</s><s>After blocking with 2% human serum albumin in TPBS again overnight at 48C, human sera were added from a 96-well plate as four 25 mL/well replicates and incubated at 48C overnight, followed by 3 washes with TPBS and 3 washes with water.</s><s>Thereafter, 25 mL/well antigen solution containing 4 mg of BHHCT (Sigma) conjugated (molar ratio, 1:30) and europium (Sigma) saturated IL-24 (Miltenyi Biotec) per 10 mL of 50 mmol/L DTPA-purified BSA (PerkinElmer, Waltham, Mass) in 50 mmol/L Tris buffer (pH 8) was added and incubated at 48C for 1 hour.</s><s>After washing 10 times with water, 25 mL of DELFIA enhancer solution (PerkinElmer) was added to each well.</s><s>Plates were measured in a Victor V reader (PerkinElmer) with standard settings.</s></p><p><s>We report mean values of a total of 1062 patients with CSU and 482 healthy control subjects, with each subject tested up to 4 times in 4 independent experiments with similar results.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Calculation of IgE-anti-IL-24 units, fractions, and cutoffs</head><p><s>Recombinant IgE-anti-green fluorescent protein (Bio-Rad Laboratories, Munich, Germany) was used to generate a standard curve to calculate IgE-anti-IL-24 values in international units per milliliter of serum measured by means of ELISA and IgE-anti-IL-24 values in international units per protein spot by using a microarray.</s><s>The sum of autoreactive IgE, as detected by using the microarray, was calculated based on IgE-anti-IL-24 protein spots, which allowed us to determine the percentage of IgE-anti-IL-24 of all detectable autoreactive IgE.</s><s>Because of several calculation steps, the values can be viewed as an approximation.</s><s>Total IgE levels measured by the Central Laboratory of Charit e-Universit€ atsmedizin Berlin were used to calculate the percentage of ELISA-based IgE-anti-IL-24.</s><s>The cutoff for increased IgE-anti-IL-24 ELISA values was calculated according to the receiver operating characteristic curve by using the Youden index.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessment of basophil numbers</head><p><s>Blood basophil numbers were determined by the Central Laboratory of the Charit e-Universit€ atsmedizin Berlin by using an automated hematocytometer.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>Normal distribution was tested with the D'Agostino-Pearson omnibus test, and an approximately Gaussian distribution served as a basis to perform Student t and ANOVA tests corrected for multiple testing by using the Holm-Sidak method.</s><s>The null hypothesis of random results was rejected if the P value was very small (ie, P &lt; .05).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients with CSU frequently exhibit IgE against many autoantigens</head><p><s>All 7 patients with CSU, patients with IdA, and healthy control subjects exhibited IgE-AAbs against multiple autoantigens, as assessed by using microarray analyses of serum reactivity to 9374 human proteins ( Considering the IgE-AAs recognized only by serum from a patient with CSU, Tables I and II show that 222 autoallergens were recognized by at least 1 patient.</s><s>As the number of patients increased, the number of common autoallergens decreased, so that the IgE of half of the patients reacted to 77 autoantigens, whereas 31 autoallergens were recognized by 71% of patients, and only 3 autoallergens are fully shared autoallergens recognized by all patients with CSU.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accessibility of CSU-specific IgE-AAbs to autoantigens expressed in the skin</head><p><s>Of the 31 autoantigens to which most (71%) of the patients with CSU had IgE-AAbs, 8 were accessible, 4 were soluble, and 4 were membrane-bound autoallergens.</s><s>In contrast, the other 23 IgE-AAs were intracellular and therefore are unlikely to be accessible.</s><s>Of the 8 accessible IgE-AAs, all can be expressed in the skin, but only 1, IL-24, was detected by IgE-AAbs of all 7 patients with CSU (Fig <ref type="figure" target="#fig_1">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IgE-anti-IL-24 is the most abundant IgE-AAb in patients with CSU</head><p><s>In all patients with CSU analyzed by using a protein array, IgE-anti-IL-24 showed the highest serum levels of all IgE-AAbs detected.</s><s>Up to 1.1% (mean 6 SD, 0.6% 6 0.24%) of the total detectable IgE-AAbs in patients with CSU was IgE-anti-IL-24.</s><s>IgE-anti-IL-24 serum levels did not correlate with total IgE (r 5 0.002, P 5 .840)</s><s>or total IgE-AAb levels.</s><s>None of the 7 patients with CSU had detectable IgG-anti-IL-24 serum levels.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IgE-anti-IL-24 and IL-24 induce mast cell degranulation</head><p><s>PSCMCs were sensitized with purified total IgE from patients with CSU, healthy control subjects, or with purified IgE-anti-IL-24.</s><s>IL-24 induced degranulation in cells that had been preincubated with purified IgE from patients with CSU but not healthy control subjects (Fig <ref type="figure" target="#fig_4">3, A</ref>).</s><s>Mast cells also showed degranulation after sensitization with purified IgE-anti-IL-24 and challenge with IL-24 (Fig 3 <ref type="figure">, B</ref>).   IgE-anti-IL-24 levels are greater and more often increased in patients with CSU compared with those in healthy control subjects.</s><s>A, Patients with CSU have 2.2-fold higher serum levels of IgE-anti-IL-24, as determined by means of ELISA.</s><s>Patients with CSU: mean 6 SEM 5 0.5 6 0.2 IU/mL (median, 0.49 IU/mL; range, 0.0-2.3</s><s>IU/mL); healthy subjects: mean 6 SEM 5 0.3 6 0.1 IU/mL (median, 0.3 IU/mL; range, 0.1-0.6</s><s>IU/mL).</s><s>The box shows 10% to 90% percentiles.</s><s>B, Compared with healthy control subjects, patients with CSU exhibit a higher prevalence of increased IgE-anti-IL-24 levels.</s><s>C, Receiver operating characteristic analyses of ELISA-based measurements show that the cutoff for an increased IgE-anti-IL-24 value is 0.33 IU/mL (dotted line), as determined by using the Youden index, with a specificity of 80% and sensitivity of 80%.</s><s>All 3 panels show the same data from one representative measurement from 716 patients with CSU and 332 healthy control subjects of 4 independent measurements, with a total of 1062 patients with CSU and 482 healthy control subjects, showing similar results.</s><s>***P &lt; .001.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IgE-anti-IL-24 is a sensitive and specific marker of CSU</head><p><s>To further investigate the association of IgE-anti-IL-24 and CSU, we developed and used an IgE-anti-IL-24-specific ELISA to measure serum levels in patients with CSU and healthy control subjects.</s><s>In combined data from all tested patients with CSU (n 5 1062) and healthy control subjects (n 5 482), the mean 6 SD IgE-anti-IL-24 serum levels were 0.52 6 0.24 IU/mL (median, 0.49 IU/mL; range, 0.00-2.33</s><s>IU/mL) and 0.27 6 0.08 IU/mL (median, 0.26 IU/mL; range, 0.10-0.61</s><s>IU/mL; P 5.001), respectively (Fig <ref type="figure" target="#fig_5">4</ref>).</s><s>Eight hundred forty-seven (80%) of 1062 patients with CSU exhibited higher than normal IgE-anti-IL-24 serum levels compared with 99 (20%) of 482 healthy control subjects (P &lt;.0001) based on the calculated cutoff of 0.33 IU/mL.</s><s>IgE-anti-IL-24 measurement showed acceptable predictive properties for CSU, with a sensitivity of 80% (95% CI, 76% to 83%), a specificity of 80% (95% CI, 75% to 84%), and a likelihood ratio of 3.89 (Fig <ref type="figure" target="#fig_5">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IgE-anti-IL-24 levels in patients with CSU correlate with disease activity</head><p><s>Microarray-based IgE-anti-IL-24 levels correlated with CSU activity, as assessed by using UAS7 (P 5 .03;</s><s>Fig <ref type="figure">5, A</ref>).</s><s>ELISA-based measurements also showed that relative IgE-anti-IL-24 levels were linked to disease activity, although weakly (Fig 5 <ref type="figure">, B and C</ref>).</s><s>Relative IgE-anti-IL-24 levels showed a negative association with blood basophil counts (Fig 5 <ref type="figure">, D</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>This study shows that patients with CSU produce IgE against a wide array of diverse autoantigens that are distinct from those in patients with IdA and healthy control subjects.</s><s>Further analyses showed IL-24 to be a common, functional, and specific target of IgE in patients with CSU.</s><s>These findings support a role for IgE directed to dermal autoantigens, of which IL-24 is the first to be identified, in the pathogenesis of CSU.</s></p><p><s>This study has performed full-scale screening of IgE autoreactivity in patients with CSU using more than 9000 proteins.</s><s>3]<ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref> The present study shows that the IgE of patients with CSU is directed to many more autoantigens than that of healthy control subjects (226 vs 34 autoallergens).</s></p><p><s>Patients with CSU also exhibit IgE reactivity to a larger set of different autoallergens than patients with IdA, who show similar levels of total IgE as patients with CSU.</s><s>This supports the conclusion that the IgE reactivities detected are specific rather than artifacts caused by increased total IgE levels.</s><s>An important question that needs to be addressed by future studies is whether each autoallergen in patients with CSU is detected by one specific IgE or whether there are some IgEs that recognize several autoallergens.</s><s>Because we cannot answer this question at present, we have assumed in our calculation of IgE-anti-IL-24 levels that all recognized autoallergens are bound by a monospecific IgE.</s><s>However, because it is possible that IgE-anti-IL-24 is multivalent, in which case only a fraction will be bound to IL-24 in the microarray, this would cause an underestimation of the international units per milliliter level of our IgE-anti-IL-24 results.</s><s>One thing that is very clear from the Venn diagram (Fig <ref type="figure" target="#fig_3">2</ref>) is that the majority of IgEs of patients with CSU, patients with IdA, and healthy control subjects bind to different, group-specific autoallergens.</s><s>We have explored further only the IgE-AAbs in sera from patients with CSU.</s></p><p><s>For an IgE-AA to be involved in the pathogenesis of CSU, it would need to both be present in the skin and accessible to mast cell-bound IgE.</s><s>Eight of 226 IgE-AAs from patients with CSU fulfill these criteria and are therefore likely candidates for causing IgE-dependent skin mast cell activation in patients with CSU.</s><s>Of these, IL-24 is of prime interest for 3 reasons: (1) IgE against IL-24 is present in the sera of most patients with CSU; (2) IL-24 is present in a soluble form in the skin <ref type="bibr" target="#b19">20</ref> ; and (3) IgE-anti-IL-24 had the highest serum levels of all IgE-AAbs detected, with about 1% of the total IgE in patients with CSU directed to this cytokine.</s><s>This 1% level suggests clinical relevance because it is higher than the clinically relevant 0.2% of IgE to b-lactam antibiotics <ref type="bibr" target="#b20">21</ref> and similar to 1.4% for Cor a 14 and 3.2% for Ara h 2 <ref type="bibr" target="#b21">22</ref> in patients with allergies to these allergens.</s></p><p><s>A further requisite for IgE-anti-IL-24 to be involved in the pathogenesis of CSU would be its ability to activate mast cells to release histamine.</s><s>This was confirmed by loading cultured human mast cells with IgE derived from the serum of patients with CSU, followed by challenge with IL-24.</s><s>Presently, we do not know and can only speculate whether the biological effects of IL-24, other than being a target of IgE, are relevant in the pathogenesis of CSU.</s><s>]<ref type="bibr" target="#b27">[28]</ref> In mouse models of psoriasis, IL-24 is induced by TNF in keratinocytes, and inflammation is dependent on this IL-24 induction. <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b28">29</ref></s><s>Unlike IL-10, IL-24 is not immunosuppressive but leads to a broad stimulation of various immune cells and functions. <ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b30">31</ref></s><s>n contrast to previous studies, our microarray screen did not identify thyroid peroxidase (TPO) as a common IgE-AA. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b31">32</ref></s><s>he reasons for this are currently unclear but might include differences in the glycosylation, folding, or other features of the TPO used or quenching of the IgE-anti-TPO signal in our assay by the presence of IgG-anti-TPO, or it might be that IgE-anti-TPO has a higher affinity to other autoantigens and therefore binds to a different spot on our microarray.</s></p><p><s>Sir Bradford Hill's 6th criterion for causality states that demonstration of a biological gradient can be associated with increased symptoms. <ref type="bibr" target="#b6">7</ref></s><s>Our finding that IgE-anti-IL-24 levels in patients with CSU, as assessed by using either a microarray or ELISA, are linked to disease activity supports this criterion.</s></p><p><s>The negative association with blood basophil counts might be the consequence of basophil activation by IgE-anti-IL-24 in the blood. <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b32">33</ref></s><s>he strength of this study is that it shows a marked increase in IgE-anti-IL-24 values in patients with CSU compared with healthy donors.</s><s>We used a comprehensive array of autoantigens, included IgE-matched control samples and normal donors to rule out effects that are based on higher total IgE levels and confirmed our microarray results in large populations of patients and healthy control subjects by means of ELISA.</s><s>A further strength of this study is that it provides ex vivo evidence for the bioactivity of autoreactive IgE and associations with disease activity, both of which suggest pathophysiologic relevance.</s></p><p><s>A weakness of the study is that we also identified IgEanti-IL-24 in some healthy donors, although at markedly lower concentrations.</s><s>G 5. Higher IgE-anti-IL-24 serum levels are associated with higher disease activity and lower basophil counts.</s><s>A, Higher IgE-anti-IL-24 values are linked to higher levels of disease activity, as assessed by using the UAS7 in 5 of the 7 patients with CSU tested by using a microarray (for 2 patients with CSU, no UAS7 score was available).</s><s>B, Higher levels of relative (to total IgE) IgE-anti-IL-24 tested by means of ELISA are linked to higher disease activity, as assessed by using the UAS7, which reflects disease activity during the 7 days before drawing blood (n 5 52, averaged by pruning from n 5 580 [ie, each data point shown was averaged from 15 original data points for visualization purposes]).</s><s>C, Higher relative IgE-anti-IL-24 levels, as determined by means of ELISA, are linked to higher CSU disease activity on the day the blood was drawn, as assessed by using the UAS.</s><s>D, Higher relative IgE-anti-IL-24 levels are associated with lower blood basophil counts.</s><s>Linear (Fig <ref type="figure">5</ref> A further important weakness of this study is that we cannot yet clarify whether IL-24 is the most specific and relevant autoallergen in patients with CSU because we screened only a fraction of the human proteome, with only the major protein variants of each protein included.</s><s>Also, we calculated the concentration of IgE-anti-IL-24 based on recombinant IgEanti-green fluorescent protein, which might have a much stronger affinity.</s><s>If IgE binding to IL-24 is only one hallmark of autoreactive IgE and is bound also to other autoallergens on the array, the IgE-anti-IL-24 concentration might be largely underestimated.</s></p><p><s>In conclusion, IL-24 has been identified as a common, specific, and functional autoantigen of IgE antibodies in patients with CSU.</s><s>Higher IgE-anti-IL-24 values were associated with higher disease activity.</s><s>This demonstration of autoreactive IgE in patients with CSU might explain, at least in part, the clinical success of treatment of the disease with the anti-IgE agent omalizumab.</s><s>New assays for measuring autoreactive IgE, including IgE-anti-IL-24, might help in the clinical management and monitoring of treatment responses in patients with CSU.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>Abbreviations usedCSU: Chronic spontaneous urticaria IdA: Idiopathic anaphylaxis IgE-AA: Autoantigen recognized by IgE IgE-AAb: IgE autoantibody PSCMC: Peripheral CD34 1 stem cell-derived mast cell TPBS: PBS with 0.05% Tween-20 TPO: Thyroid peroxidase UAS7: 7-Day urticaria activity score</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>FIG 1 .</head><label>1</label><figDesc><div><p><s>FIG 1. Selection process of IL-24 as a specific, accessible, and skinexpressed autoantigen detected by IgE of patients with CSU.</s><s>Accessible autoantigens (AAs) are those secreted by cells or that are membrane bound.</s><s>IgE-anti-IL-24 was detected in all patients with CSU but none of the patients with IdA or healthy control subjects.</s></p></div></figDesc><graphic coords="2,310.85,65.59,227.25,313.63" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>Fig 1).</s><s>IgE-AAbs from patients with CSU recognized a mean 6 SD of 95 6 66 autoantigens, patients with IdA recognized a mean 6 SD of 105 6 63 autoallergens, and healthy control subjects recognized a mean 6 SD of 28 6 11 autoallergens.</s><s>The distribution of autoallergens recognized by each group is shown in the Venn diagram (Fig 2 and Tables I and II ).</s><s>Of the total 226 autoantigens recognized by IgE (IgE-AAs) from at least 1 patient with CSU, only 4 were also recognized by IgE from a patient with IdA and none by IgE from any healthy control subjects.</s><s>IgE from patients with CSU was more heterogeneous and recognized more different autoantigens than IgE from patients with IdA (226 vs 161).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>FIG 2 .</head><label>2</label><figDesc><div><p><s>FIG 2. Number of autoantigens detected by IgE (autoallergens) in patients with CSU, patients with IdA, and/or healthy control subjects.</s></p></div></figDesc><graphic coords="3,47.00,65.60,227.25,112.71" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>FIG 3 .</head><label>3</label><figDesc><div><p><s>FIG 3. IL-24 induces degranulation in mast cells sensitized with purified IgE or IgE-anti-IL-24.</s><s>Peripheral stem cell-derived mast cells were incubated with purified IgE (A) or IgE-anti-IL-24 (B) derived from the sera of patients with CSU or (only in Fig 3, A) healthy control subjects before stimulation with anti-IgE, coated IL-24, or vehicle as a control.</s><s>Data shown are mean values of absolute release and SEMs.</s><s>Spontaneous release was 12%.</s><s>No specific mast cell degranulation was induced by IL-24 alone.</s><s>Fig 3, A, shows pooled data from 4 experiments by using the same IgE preparation but different cell donors.</s><s>Data shown in Fig 3, B, are from one of 3 experiments with similar results.</s><s>***P &lt; .005</s><s>and ****P &lt; .0001.</s></p></div></figDesc><graphic coords="4,103.07,65.59,382.76,249.68" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>FIG 4 .</head><label>4</label><figDesc><div><p><s>FIG 4. IgE-anti-IL-24 levels are greater and more often increased in patients with CSU compared with those in healthy control subjects.</s><s>A, Patients with CSU have 2.2-fold higher serum levels of IgE-anti-IL-24, as determined by means of ELISA.</s><s>Patients with CSU: mean 6 SEM 5 0.5 6 0.2 IU/mL (median, 0.49 IU/mL; range, 0.0-2.3</s><s>IU/mL); healthy subjects: mean 6 SEM 5 0.3 6 0.1 IU/mL (median, 0.3 IU/mL; range, 0.1-0.6</s><s>IU/mL).</s><s>The box shows 10% to 90% percentiles.</s><s>B, Compared with healthy control subjects, patients with CSU exhibit a higher prevalence of increased IgE-anti-IL-24 levels.</s><s>C, Receiver operating characteristic analyses of ELISA-based measurements show that the cutoff for an increased IgE-anti-IL-24 value is 0.33 IU/mL (dotted line), as determined by using the Youden index, with a specificity of 80% and sensitivity of 80%.</s><s>All 3 panels show the same data from one representative measurement from 716 patients with CSU and 332 healthy control subjects of 4 independent measurements, with a total of 1062 patients with CSU and 482 healthy control subjects, showing similar results.</s><s>***P &lt; .001.</s></p></div></figDesc><graphic coords="4,79.20,406.09,430.56,163.67" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head></head><label></label><figDesc><div><p><s>FIG 5. Higher IgE-anti-IL-24 serum levels are associated with higher disease activity and lower basophil counts.</s><s>A, Higher IgE-anti-IL-24 values are linked to higher levels of disease activity, as assessed by using the UAS7 in 5 of the 7 patients with CSU tested by using a microarray (for 2 patients with CSU, no UAS7 score was available).</s><s>B, Higher levels of relative (to total IgE) IgE-anti-IL-24 tested by means of ELISA are linked to higher disease activity, as assessed by using the UAS7, which reflects disease activity during the 7 days before drawing blood (n 5 52, averaged by pruning from n 5 580 [ie, each data point shown was averaged from 15 original data points for visualization purposes]).</s><s>C, Higher relative IgE-anti-IL-24 levels, as determined by means of ELISA, are linked to higher CSU disease activity on the day the blood was drawn, as assessed by using the UAS.</s><s>D, Higher relative IgE-anti-IL-24 levels are associated with lower blood basophil counts.</s><s>Linear (Fig5, A-C) and sigmoidal (Fig 5, D) regression lines are shown with 95% CIs as dotted lines.</s></p></div></figDesc><graphic coords="6,103.18,65.59,382.55,302.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>TABLE II .</head><label>II</label><figDesc><div><p><s>Total number of autoantigens detected by IgE in the sera of patients with CSU and control subjects</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell cols="3">Patients with CSU</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">Patients with IdA</cell><cell></cell><cell></cell><cell cols="5">Healthy control subjects</cell><cell></cell></row><row><cell>Subject no.</cell><cell>1</cell><cell>2</cell><cell>3</cell><cell>4</cell><cell>5</cell><cell>6</cell><cell>7</cell><cell>1</cell><cell>2</cell><cell>3</cell><cell>4</cell><cell>5</cell><cell>6</cell><cell>7 1</cell><cell>2</cell><cell>3</cell><cell>4</cell><cell>5</cell><cell>6</cell><cell>7</cell></row><row><cell cols="21">Absolute no. of IgE-AAs/subject 29 40 49 68 116 166 197 10 24 112 128 147 157 158 0 30 32 32 32 34 34</cell></row><row><cell>Mean 6 SD no. of IgE-AAs</cell><cell></cell><cell></cell><cell></cell><cell>95 6 66</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>105 6 63</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>28 6 11</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median (range) no. of IgE-AAs</cell><cell></cell><cell></cell><cell></cell><cell cols="2">68 (29-197)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">128 (10-158)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>32 (0-34)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Total no. of IgE-AAs</cell><cell></cell><cell></cell><cell></cell><cell>226</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>161</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>34</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="10">The bottom line shows the total number of autoantigens recognized within each group of 7 subjects.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE I .</head><label>I</label><figDesc><div><p><s>Patients with CSU exhibit IgE reactivity to many autoantigens (autoallergens) that are not detected by the IgE of patients with IdA or healthy control subjectsThe table shows numbers of specific IgE-AAs shared by all patients with CSU (7/7), shared by some patients with CSU (2/7 to 6/7), and found in any of the patients with CSU (1/7).</s></p></div></figDesc><table><row><cell>Rate (%) of patients with CSU</cell><cell cols="7">1/7 (14%) 2/7 (29%) 3/7 (43%) 4/7 (57%) 5/7 (71%) 6/7 (86%) 7/7 (100%)</cell></row><row><cell>No. of AAs not detected by IgE in any of the control subjects</cell><cell>222</cell><cell>180</cell><cell>128</cell><cell>77</cell><cell>31</cell><cell>19</cell><cell>3</cell></row><row><cell>AAs, Autoantigens.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 3</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGY CLIN IMMUNOLSEPTEMBER 2018</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>We thank the Mast Cell-driven Diseases and their Differential Diagnoses (MAD 3 ) team of the Dermatological Allergy (DEAL) group at Charit e for help and support and Professor Margitta Worm for providing sera of patients with IdA.</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The allergic aspects of urticaria and angioneurotic oedema</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Bray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Postgrad Med J</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="112" to="115" />
			<date type="published" when="1942">1942</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Brzoza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Canonica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="868" to="887" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Basophilic leucopenia in different forms of urticaria</title>
		<author>
			<persName><forename type="first">H</forename><surname>Rorsman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Allergol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="168" to="184" />
			<date type="published" when="1962">1962</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">IgE antithyroid microsomal antibodies in a patient with chronic urticaria</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bar-Sela</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Reshef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">A</forename><surname>Mekori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="1216" to="1217" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">IgE mediated autoallergy against thyroid peroxidase-a novel pathomechanism of chronic spontaneous urticaria?</title>
		<author>
			<persName><forename type="first">S</forename><surname>Altrichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Peter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pisarevskaja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">e14794</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Significantly high levels of anti-dsDNA immunoglobulin E in sera and the ability of dsDNA to induce the degranulation of basophils from chronic urticaria patients</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Hatada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kashiwakura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Fujisawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sasaki-Sakamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Terui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Arch Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="154" to="158" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Autoimmune chronic spontaneous urticaria: what we know and what we do not know</title>
		<author>
			<persName><forename type="first">P</forename><surname>Kolkhir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Schmetzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="1772" to="1781" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>e1</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Autoantigen microarray for high-throughput autoantibody profiling in systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">H</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">Z</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genomics Proteomics Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="210" to="218" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Self-reactive IgE exacerbates interferon responses associated with autoimmunity</title>
		<author>
			<persName><forename type="first">J</forename><surname>Henault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Riggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Karnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Liarski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Shirinian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Immunol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="196" to="203" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Basophils in chronic urticaria</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Grattan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Investig Dermatol Symp Proc</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="139" to="140" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">A novel method to generate and culture human mast cells: peripheral CD341 stem cell-derived mast cells (PSCMCs)</title>
		<author>
			<persName><forename type="first">O</forename><surname>Schmetzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Valentin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Smorodchenko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Domenis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Siebenhaar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol Methods</title>
		<imprint>
			<biblScope unit="volume">413</biblScope>
			<biblScope unit="page" from="62" to="68" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">IgE antithyroid antibodies in patients with Hashimoto&apos;s disease and chronic urticaria</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Concha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Szema</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Dattwyler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Carlson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy Asthma Proc</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="293" to="296" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Assessment of autoimmunity in patients with chronic urticaria</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Balakrishnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Kochan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Kinet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Kaplan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="461" to="465" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Human anti-FcepsilonRIalpha autoantibodies isolated from healthy donors cross-react with tetanus toxoid</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Horn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gerster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ochensberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Derer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Kricek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Jouvin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Immunol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1139" to="1148" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship</title>
		<author>
			<persName><forename type="first">E</forename><surname>Fiebiger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hammerschmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stingl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="243" to="251" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients?</title>
		<author>
			<persName><forename type="first">E</forename><surname>Fiebiger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Holub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Reininger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woisetschlager</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="2606" to="2612" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria</title>
		<author>
			<persName><forename type="first">N</forename><surname>Niimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Francis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Kermani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Donnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Hide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kobza-Black</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="1001" to="1006" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Francis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Grattan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hakimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Kochan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Greaves</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">328</biblScope>
			<biblScope unit="page" from="1599" to="1604" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Grattan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Francis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Greaves</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Allergy</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="695" to="704" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Poindexter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Powis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jen</forename><forename type="middle">E</forename><surname>Caudle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Chada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="714" to="722" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">High serum beta-lactams specific/total IgE ratio is associated with immediate reactions to beta-lactams antibiotics</title>
		<author>
			<persName><forename type="first">A</forename><surname>Vultaggio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Virgili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gaeta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Romano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Maggi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Matucci</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">e0121857</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The component-specific to total IgE ratios do not improve peanut and hazelnut allergy diagnoses</title>
		<author>
			<persName><forename type="first">L</forename><surname>Grabenhenrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lange</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hartl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kalb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ziegert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Finger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="1751" to="1760" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>e8</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Hofmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rosen-Wolff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Tsokos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Hedrich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="116" to="127" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Andoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shioya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nishida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bamba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tsujikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kim-Mitsuyama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">183</biblScope>
			<biblScope unit="page" from="687" to="695" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Expression of interleukin (IL)-19 and IL-24 in inflammatory bowel disease patients: a cross-sectional study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Fonseca-Camarillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Furuzawa-Carballeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Granados</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Yamamoto-Furusho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Immunol</title>
		<imprint>
			<biblScope unit="volume">177</biblScope>
			<biblScope unit="page" from="64" to="75" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Molecular mechanisms governing IL-24 gene expression</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sahoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Im</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immune Netw</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">X</forename><surname>Leng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Q</forename><surname>Ye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Ther Targets</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="119" to="126" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis-like skin inflammation in mice</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kumari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Bonnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Ulvmar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wolk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Karagianni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Witte</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="899" to="911" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Sa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Valdez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">178</biblScope>
			<biblScope unit="page" from="2229" to="2240" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">The protein product of the tumor suppressor gene, melanoma differentiationassociated gene 7, exhibits immunostimulatory activity and is designated IL-24</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Caudell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Mumm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Poindexter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ekmekcioglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Mhashilkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">H</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="6041" to="6046" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Nemunaitis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Senzer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Ther</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="160" to="172" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Lack of a role for crossreacting anti-thyroid antibodies in chronic idiopathic urticaria</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Mozena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tinana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Negri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Steinke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Borish</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="1860" to="1865" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Potential blood biomarkers in chronic spontaneous urticaria</title>
		<author>
			<persName><forename type="first">P</forename><surname>Kolkhir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Andre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Allergy</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="19" to="36" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Detection of one VH antibody sequence in both healthy donors and urticaria patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Fux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Stadler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Stadler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Miescher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol Methods</title>
		<imprint>
			<biblScope unit="volume">307</biblScope>
			<biblScope unit="page" from="107" to="117" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
